Measurement of ab-initio physiomarker using wearable sensors to predict aneurysm growth and formation

项目摘要 动脉瘤是血管的永久性局部扩张。生长、破裂和 主动脉瘤的夹层导致显著的患者死亡率。当前 护理标准依赖于1至5年的反应性监测策略， 监测动脉瘤的生长速度该项目旨在验证预测的准确性， 一个从头开始的生理标记物，用于诊断动脉瘤的生长和夹层， 初步评估。通过捕捉驱动动脉瘤的潜在物理机制 发展，生理标志物可用于确定是否血液的横截面 血管将永久扩张-无论动脉瘤将随时间增长还是保持停滞。 这种预测策略可以在最初的治疗或手术干预中提供信息。 对患者进行评估，而不是等到随访时才监测生长。具体 该项目有三个目标。首先是验证生物力学的准确性， 生理标志物，确定其与组织重塑模式的关系，并量化 非线性效应，使用已建立的体外实验。血流动力学和血管壁 将控制性能以检查增长和停滞状态。二是 验证生理标志物在马凡氏病等相关神经病变患者中的准确性 综合征或双尖主动脉瓣，这可能是典型的混淆因素， 基于回归的方法，但预计不会影响这种从头开始的框架。回顾性 将进行观察性研究，以检查生理标志物在 这些因素的存在。最后，将使用灵活、可穿戴的 传感器，无论是与超声心动图或作为一个独立的平台。这将是 通过1至2年的仔细对照、前瞻性观察研究进行。两 模式将提供一种更安全，更便宜，更准确的方法来预测动脉瘤的生长， 解剖如果独立的传感器平台在测量温度方面表现出足够的精度， 物理标志物，它将使更频繁，在家里监测动脉瘤，类似于如何 血压监测器可用于跟踪高血压的发展。而且 作为常规检查的一部分， 健康检查。

Project Summary Aneurysms are permanent, local dilations of the blood vessel. The growth, rupture and dissection of aortic aneurysms induce a significant rate of patient mortality. The current standard of care relies on a reactive strategy of surveillance over a period of 1 to 5 years to monitor the growth rate of an aneurysm. This project seeks to validate the predictive accuracy of an ab-initio physiomarker in diagnosing both the growth and dissection of an aneurysm during an initial evaluation. By capturing the underlying physical mechanism driving aneurysm development, the physiomarker can be used to determine whether a cross section of the blood vessel will dilate permanently—whether an aneurysm will grow or remain stagnant over time. This predictive strategy can inform immediate treatment or surgical intervention at the initial evaluation of the patient instead of waiting until follow-up to monitor for growth. The specific aims of the project are threefold. The first is to verify the biomechanical accuracy of the physiomarker, determine its relationship with tissue remodeling modalities, and quantify nonlinear effects using an established in vitro experiment. The hemodynamic and vessel wall properties will be controlled to examine the growth and stagnation regimes. The second is to validate the accuracy of the physiomarker in patients with associated aortopathies like Marfan syndrome or biscuspid aortic valves, which may typically act as confounding factors for regression-based methods but are not expected to affect this ab-initio framework. Retrospective observational studies will be performed to examine the accuracy of the physiomarker in the presence of these factors. Lastly, the physiomarker will be measured using flexible, wearable sensors, either in conjunction with echocardiography or as a standalone platform. This will be carried out via carefully controlled, prospective observational studies over 1 to 2 years. Both modalities will offer a safer, cheaper and more accurate way to predict aneurysm growth and dissection. If the standalone sensor platform exhibits sufficient accuracy in measuring the physiomarker, it will enable more frequent, at home monitoring of aneurysms, akin to how blood pressure monitors can be used to track the development of hypertension. Additionally, it will enable much broader screening for aneurysms in the general population as part of routine health checkups.